POZEN POZN

… and Chief Commercial Officer of POZN , we discuss the implications of ..... migrane drug MT 400. Last week, Pozen Inc. ( POZN ) announced a licensing deal with ..... Switzerland and Norway. MT 400 is Pozen 's proprietary combination of sumatriptan …

* Says in talks with potential partners on lower dose of stomach ulcer drug

By Kapitall : Do you like to follow the buying trends of smart money investors like hedge fund managers? For a closer look at stocks that the smart money is buying up, we ran a screen. We began by screening the healthcare sector for stocks that appear undervalued relative to earnings growth, with

By StockPandit : Next week is a busy earnings season, with many quarterly earnings releases scheduled and a bunch of stocks to watch. However, my focus is on biotechnology and drugs stocks that have earnings due in the next week. This article provides earnings previews on several stocks to consider

… cruelest month." They both must have been taking about pharmaceutical companies in general and Dendreon ( DNDN ) and Pozen ( POZN ) in particular. More on these companies in a minute. One thing's sure: you need a cast iron stomach to invest …

By Scott Matusow : I usually do not write perceived 'negative' articles with an opinion to short a stock, but the following company may be a good short candidate for the midterm. I would like to caution traders to be careful when considering a short and to fully understand the risks that are ...

… will "pursue vigorously" its antitrust lawsuit against Apple and two publishing houses over allegations that they conspired to fix prices for electronic books, the head of the agency's antitrust division, Sharis Pozen , said on Thursday.

Pozen ( POZN ) +13.3% premarket after the biotech company announces positive top-line results from two pivotal Phase 3 clinical trials …